Early nutritional screening may benefit patients receiving vismodegib
the ONA take:
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib, a new study published online ahead of print in the journal Supportive Care in Cancer has suggested.
Although vismodegib is effective in the treatment of this type of skin cancer, weight loss and dysgeusia (persistent abnormal taste or change in taste) are common treatment-related adverse events.
Therefore, researchers sought to monitor the nutritional status of vismodegib-treated patients, as well as assess the incidence of dysgeusia and the benefit of early nutritional management.
For the prospective study, researchers enrolled 45 patients with locally advanced or metastatic basal cell carcinoma who started vismodegib between October 2011 and May 2013 at Nantes University Hospital in France.
Of those, 24 patients had not received any specific nutritional management while 21 patients were evaluated by a physician from the Nutrition Support Unit and received dietary counseling at the time of vismodegib initiation.
Results showed that 24% of patients receiving dietary counseling were undernourished at vismodegib initiation and the 6-month cumulative incidence of dysgeusia was 71%.
Researchers found that 38% of patients receiving dietary counseling experienced a weight loss greater than 5% compared with 54% of those who did not receive any specific nutritional management.
“The potential benefit of nutritional support in this setting warrants further investigation,” the authors conclude.
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer
- Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women
- Live-streamed Videos Address End-of-Life Planning, Decision-making
- Metastatic Disease Linked to Patients Reporting Diminished QoL
- History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis
- Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|